First Tracks Biotherapeutics Inc
Healthcare
NASDAQ:TRAX · NASDAQ Global Select
Market Cap $612.54M Beta 0.00 P/E (TTM) -6.1
$17.42 -4.87%
-$0.89 today
52W Low $14.72High $26.80
Vol 1.44M · Avg 0.43M
EPS (TTM) -$2.81Biotechnology
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:TRAX · Revenue to Net Income
No earnings data available.
Income Statement
Annual data · 3 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $888.0M | $1.0B | $809.6M |
| Cost of Revenue | $139.6M -8.4% | $152.3M | $0 | -$1.7B | $344.8M | $725.6M |
| Gross Profit | -$139.6M +8.4% | -$152.3M | $0 | $11.6B | $10.3B | $8.9B |
| Gross Margin | — | — | — | 26.4% | 45.5% | 9.8% |
| Research & Development | $139.6M -8.4% | $152.3M +56.1% | $97.6M | $1.2B | $378.4M | $983.2M |
| Selling, General & Admin | $39.4M +37.0% | $28.8M +37.8% | $20.9M | $811.0M | $1.4B | $620.6M |
| Operating Expenses | $39.4M +37.0% | $28.8M -75.7% | $118.5M | -$15.9B | $3.6B | $5.3B |
| Depreciation & Amortization | $559.0K -76.7% | $2.4M +0.9% | $2.4M | $419.0M | $1.2B | $374.2M |
| EBITDA | -$178.4M +0.1% | -$178.7M -53.9% | -$116.1M | $10.0B | $12.6B | -$15.2B |
| EBITDA Margin | — | — | — | 14.3% | 10.0% | 5.6% |
| Operating Income | -$179.0M +1.2% | -$181.1M -52.9% | -$118.5M | $9.0B | $10.6B | $12.3B |
| Operating Margin | — | — | — | 11.2% | 18.7% | 16.6% |
| Interest Income | $0 -100.0% | $17.4M +41.2% | $12.3M | $875.4M | $1.3B | -$1.5B |
| Interest Expense | $0 | $0 | $0 | $801.2M | $969.2M | $1.1B |
| Other Income / Expenses | $12.9M -25.7% | $17.4M +41.3% | $12.3M | $368.6M | -$1.6B | -$1.5B |
| Income Before Tax | -$166.1M -1.5% | -$163.7M -54.2% | -$106.2M | $13.9B | -$15.6B | $3.3B |
| Pre-Tax Margin | — | — | — | 15.4% | 13.3% | 20.8% |
| Income Tax Expense | $0 | $0 | $0 | $375.6M | $666.8M | $1.3B |
| Net Income | -$166.1M -1.5% | -$163.7M -54.2% | -$106.2M | $5.1B | $5.0B | $4.9B |
| Net Margin | — | — | — | 47.3% | 7.4% | 12.4% |
| EPS (Basic) | $0 | $0 +100.0% | -$3 | $591.2M | $1.2B | $400.8M |
| EPS (Diluted) | $0 | $0 +100.0% | -$3 | $777.4M | $620.6M | $766.2M |
| Weighted Avg Shares | $0 | $0 -100.0% | $34.7M | $724.2M | $892.2M | $757.8M |
| Weighted Avg Shares (Diluted) | $0 | $0 -100.0% | $34.7M | $566.0M | $319.6M | $1.2B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
No competitor data available.
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does TRAX generate?
First Tracks Biotherapeutics Inc (TRAX) reported $0.00 of revenue in fiscal 2025.
Is TRAX profitable?
First Tracks Biotherapeutics Inc (TRAX) reported -$166,087,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.
OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.FilingsOpen recent filings alongside price history for deeper research.